Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.24.1.1.u2
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
3 Months Ended
Mar. 31, 2024
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

Three-Month Periods Ended March 31, 

($ in thousands)

    

2024

    

2023

Qbrexza®

$

5,017

$

4,094

Accutane®

 

5,819

 

4,648

Amzeeq®

755

1,193

Zilxi®

273

314

Other / legacy

1,166

1,916

Total product revenues

$

13,030

$

12,165

Schedule of other revenue

    

Three-Month Periods Ended March 31,

($in thousands)

2024

2023

Other revenue

 

 

48

Total other revenue

$

$

48